×
About 2,853 results

ALLMedicine™ Cardiac Tamponade Center

Research & Reviews  990 results

Cardiac Tamponade complicating Ventricular Arrythmia Ablation: real life data on incide...
https://doi.org/10.1111/jce.15760
Journal of Cardiovascular Electrophysiology; Darma A, Dinov B et. al.

Nov 27th, 2022 - Cardiac tamponade during ablation procedures is a life-threatening complication. While the incidence and management of tamponade in atrial fibrillation ablation has been extensively described, the data on tamponade during ventricular ablations are...

Subacute Cardiac Tamponade Due to Tuberculous Pericarditis Diagnosed by Urine Lipoarabi...
https://doi.org/10.3390/ijerph192215143
International Journal of Environmental Research and Publi... De Vita E, Segala FV et. al.

Nov 27th, 2022 - Uganda ranks among the countries with the highest burden of TB the world and tuberculous pericarditis (TBP) affects up to 2% of people diagnosed with pulmonary tuberculosis worldwide. In Africa, it represents the most common cause of pericardial d...

Cardiac Tamponade Causing Predominant Left Atrial and Ventricular Compression After Lef...
https://doi.org/10.12659/AJCR.938115
The American Journal of Case Reports; Victor S, Hayanga JWA et. al.

Nov 26th, 2022 - BACKGROUND Cardiac tamponade is a life-threatening condition that occurs when pericardial fluid accumulates in the pericardial sac, causing compression of the heart and obstructive shock. This hemodynamic event typically occurs in right-sided card...

Hematologic and Oncologic Emergencies.
https://doi.org/10.1097/CNQ.0000000000000440
Critical Care Nursing Quarterly; Holden K, Rao S et. al.

Nov 24th, 2022 - This article reviews both hematologic and oncologic emergencies that may be seen in the intensive care setting. Hematologic emergencies, including autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and dis...

Anesthetic Considerations in the Electrophysiology Laboratory: A Comprehensive Review.
https://doi.org/10.1053/j.jvca.2022.10.013
Journal of Cardiothoracic and Vascular Anesthesia; Alvarez CK, Zweibel S et. al.

Nov 11th, 2022 - Catheter ablation procedures for arrhythmias or implantation and/or extraction of cardiac pacemakers can present many clinical challenges. It is imperative that there is clear communication and understanding between the anesthesiologist and electr...

see more →

Clinicaltrials.gov  50 results

A Machine Learning Approach to Continuous Vital Sign Data Analysis
https://clinicaltrials.gov/ct2/show/NCT01448161

Aug 17th, 2022 - Study hypothesis: Machine Learning algorithms and techniques previously developed for use in the robotics field can be applied to the field of medicine. These state-of-the-art, feature extraction and machine learning techniques can utilize patient...

Radial accEss Crossover for PErcutaneous Coronary Procedures And ouTcome: the REPEAT Study
https://clinicaltrials.gov/ct2/show/NCT05340998

Jul 25th, 2022 - All patients who undergo to percutaneous coronary diagnostic or interventional procedures through transradial approach (TRA) will be screened for inclusion in this prospective observational study and patients with TRA failure necessitating vascula...

AtaCor Subcostal Temporary Extravascular Pacing III Study
https://clinicaltrials.gov/ct2/show/NCT04538287

Jul 7th, 2022 - Prior revisions of the study intended to evaluate multiple StealthTrac Leads (Models AC-1010, AC-1020, AC-2021 and AC-1030) to support the development of a future pivotal study. In the most recent revision of the study, an additional StealthTrac L...

Comparison of the Shukla and UN-1 Formulae in the Placement of the Umbilical Venous Catheter Among Neonates
https://clinicaltrials.gov/ct2/show/NCT05022433

May 5th, 2022 - UVC insertion has benefits and potential complications such as infection, intestinal necrosis, thrombosis, ascites, hydrothorax, cardiac tamponade, cardiac arrhythmias, pleural effusion, pericarditis and pericardial effusion. The complications may...

MERIT Study - Mistral Percutaneous Mitral Valve Repair FIM Study
https://clinicaltrials.gov/ct2/show/NCT02948231

Apr 7th, 2022 - The study is designed to clinically demonstrate device acute safety (Primary Endpoint) along with longer FU device safety and effectiveness evaluation (Secondary Endpoint). The main objectives of the study are : Evaluate the Acute safety of the im...

see more →

News  90 results

Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer
https://www.onclive.com/view/addition-of-bevacizumab-to-ixabepilone-is-effective-tolerable-in-platinum-resistant-ovarian-cancer

Mar 18th, 2022 - The combination of ixabepilone (Ixempra) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) vs ixabepilone alone in the treatment of platinum-resistant ovarian cancer, according to data from the phase 2 trial (NCT3093...

Hair Loss Drugs Ranked in Order of Efficacy
https://www.medpagetoday.com/dermatology/generaldermatology/97062

Feb 7th, 2022 - The 5-alpha reductase inhibitor (5-ARI) dutasteride (Avodart) likely is the most efficacious among the three drugs currently used to treat androgenetic alopecia (AGA), or male pattern baldness, according to a network meta-analysis. Overall rank fo...

FDA Flags Cardiac Perforation Risks During Leadless Pacemaker Implantation
https://www.medscape.com/viewarticle/963197

Nov 17th, 2021 - The US Food and Drug Administration (FDA) is reminding healthcare providers about the risk of major complications if cardiac perforation occurs during leadless pacemaker implantation. Cardiac perforation is a rare complication and the overall risk...

Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC
https://www.onclive.com/view/published-entrectinib-data-demonstrate-encouraging-responses-in-ros1-nsclc

Oct 6th, 2021 - Robert C. Doebele, MD, PhD Treatment with entrectinib (Rozlytrek) led to an overall response rate (ORR) of 77% and a median duration of response (DOR) of 24.6 months in patients with ROS1 fusion—positive non–small cell lung cancer (NSCLC), accord...

CD47 Blocker ALX148 Safe to Combine With Antibody Regimens, Chemotherapy in Gastric/GEJ and HNSCC
https://www.onclive.com/view/cd47-blocker-alx148-safe-to-combine-with-antibody-regimens-chemotherapy-in-gastric-gej-and-hnscc

Oct 6th, 2021 - The high affinity CD47 myeloid checkpoint inhibitor ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab (Herceptin), pembrolizumab (Keytruda), and multiagent chemotherapy regimens in patients with gast...

see more →

Patient Education  11 results see all →